Clinical implications of AGR2 in primary prostate cancer : Results from a large-scale study
© 2024 The Authors. APMIS published by John Wiley & Sons Ltd on behalf of Scandinavian Societies for Pathology, Medical Microbiology and Immunology..
Human anterior gradient-2 (AGR2) has been implicated in carcinogenesis of various solid tumours, but the expression data in prostate cancer are contradictory regarding its prognostic value. The objective of this study is to evaluate the expression of AGR2 in a large prostate cancer cohort and to correlate it with clinicopathological data. AGR2 protein expression was analysed immunohistochemically in 1023 well-characterized prostate cancer samples with a validated antibody. AGR2 expression levels in carcinomas were compared with matched tissue samples of adjacent normal glands. AGR2 expression levels were dichotomized and tested for statistical significance. Increased AGR2 expression was found in 93.5% of prostate cancer cases. AGR2 levels were significantly higher in prostate cancer compared with normal prostate tissue. A gradual loss of AGR2 expression was associated with increasing tumour grade (ISUP), and AGR2 expression is inversely related to patient survival, however, multivariable significance is not achieved. AGR2 is clearly upregulated in the majority of prostate cancer cases, yet a true diagnostic value appears unlikely. In spite of the negative correlation of AGR2 expression with increasing tumour grade, no independent prognostic significance was found in this large-scale study.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:132 |
|---|---|
| Enthalten in: |
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica - 132(2024), 4 vom: 12. März, Seite 256-266 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wambach, Moritz [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
AGR2 |
|---|
| Anmerkungen: |
Date Completed 14.03.2024 Date Revised 14.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/apm.13382 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367790947 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367790947 | ||
| 003 | DE-627 | ||
| 005 | 20240314235002.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240130s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/apm.13382 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1329.xml |
| 035 | |a (DE-627)NLM367790947 | ||
| 035 | |a (NLM)38288749 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wambach, Moritz |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical implications of AGR2 in primary prostate cancer |b Results from a large-scale study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.03.2024 | ||
| 500 | |a Date Revised 14.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 The Authors. APMIS published by John Wiley & Sons Ltd on behalf of Scandinavian Societies for Pathology, Medical Microbiology and Immunology. | ||
| 520 | |a Human anterior gradient-2 (AGR2) has been implicated in carcinogenesis of various solid tumours, but the expression data in prostate cancer are contradictory regarding its prognostic value. The objective of this study is to evaluate the expression of AGR2 in a large prostate cancer cohort and to correlate it with clinicopathological data. AGR2 protein expression was analysed immunohistochemically in 1023 well-characterized prostate cancer samples with a validated antibody. AGR2 expression levels in carcinomas were compared with matched tissue samples of adjacent normal glands. AGR2 expression levels were dichotomized and tested for statistical significance. Increased AGR2 expression was found in 93.5% of prostate cancer cases. AGR2 levels were significantly higher in prostate cancer compared with normal prostate tissue. A gradual loss of AGR2 expression was associated with increasing tumour grade (ISUP), and AGR2 expression is inversely related to patient survival, however, multivariable significance is not achieved. AGR2 is clearly upregulated in the majority of prostate cancer cases, yet a true diagnostic value appears unlikely. In spite of the negative correlation of AGR2 expression with increasing tumour grade, no independent prognostic significance was found in this large-scale study | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a AGR2 | |
| 650 | 4 | |a TMA | |
| 650 | 4 | |a androgen receptor | |
| 650 | 4 | |a immunohistochemistry | |
| 650 | 4 | |a prostate cancer | |
| 650 | 7 | |a Oncogene Proteins |2 NLM | |
| 650 | 7 | |a Mucoproteins |2 NLM | |
| 650 | 7 | |a AGR2 protein, human |2 NLM | |
| 700 | 1 | |a Montani, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Runz, Josefine |e verfasserin |4 aut | |
| 700 | 1 | |a Stephan, Carsten |e verfasserin |4 aut | |
| 700 | 1 | |a Jung, Klaus |e verfasserin |4 aut | |
| 700 | 1 | |a Moch, Holger |e verfasserin |4 aut | |
| 700 | 1 | |a Eberli, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Bernhardt, Marit |e verfasserin |4 aut | |
| 700 | 1 | |a Hommerding, Oliver |e verfasserin |4 aut | |
| 700 | 1 | |a Kreft, Tobias |e verfasserin |4 aut | |
| 700 | 1 | |a Cronauer, Marcus V |e verfasserin |4 aut | |
| 700 | 1 | |a Kremer, Anika |e verfasserin |4 aut | |
| 700 | 1 | |a Mayr, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Hauser, Stefan |e verfasserin |4 aut | |
| 700 | 1 | |a Kristiansen, Glen |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t APMIS : acta pathologica, microbiologica, et immunologica Scandinavica |d 1989 |g 132(2024), 4 vom: 12. März, Seite 256-266 |w (DE-627)NLM012602744 |x 1600-0463 |7 nnns |
| 773 | 1 | 8 | |g volume:132 |g year:2024 |g number:4 |g day:12 |g month:03 |g pages:256-266 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/apm.13382 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 132 |j 2024 |e 4 |b 12 |c 03 |h 256-266 | ||